The Chinese pharmaceutical market at the crossroads: Pro-competition solutions to improve access, quality and affordability

Applied Health Economics and Health Policy

Volumn 4, Issue 3, 2005, Pages 147-151

  Wang, Y Richard ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; GENERIC DRUG;

CHINA; COMPETITION; DEVELOPING COUNTRY; DRUG COST; DRUG MANUFACTURE; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH INSURANCE; HOSPITAL PHARMACY; HUMAN; PRACTICE GUIDELINE; REVIEW; UNITED STATES;

CHINA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; DRUG TOXICITY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 28444494362     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200504030-00002     Document Type: Review

References (6)

1. IMS Health. IMS market prognosis, Asia 2004-2008. London: IMS Health, 2004 May
2. Kremer M. Pharmaceuticals and the developing world. J Econ Perspect 2002 Fall; 16 (4): 67-90
3. Wang YR, Ji L, Lin YA. Intellectual property right protection for pharmaceuticals in developing countries: a case study of administrative protection in China. Pharm Dev Regul 2003; 1 (4): 277-82
4. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs: evidence from twenty-five major markets in the 1990s. Health Econ 2005 Mar; 14 (3): 269-92
5. International Conference on Harmonisation (ICH). ICH harmonised tripartite guideline. E5: Ethnic factors in the acceptability of foreign clinical data. Feb 1998. Geneva: ICH [online]. Available at URL: http://www.ich.org [Accessed 2005 Sep 2005]
6. IMS Health. MIDAS database 1998-2003. Fairfield (CT): IMS Health, 2003. (Data on file)